Anika Therapeutics (ANIK) Common Equity (2010 - 2026)

Anika Therapeutics (ANIK) has reported Common Equity for 17 consecutive years, with $137.3 million the latest figure, recorded in Q2 2026.

• On a quarterly basis, Common Equity fell 7.04% year-over-year to $137.3 million in Q2 2026; TTM through Jun 2026 was $137.3 million, a 7.04% decrease from a year earlier, with the FY2025 full-year figure at $143.5 million, down 6.83% from the prior year.
• Common Equity was $137.3 million for Q2 2026 at Anika Therapeutics, up from $133.9 million in the prior quarter.
• Over five years, Common Equity peaked at $286.2 million in Q2 2022 and troughed at $133.9 million in Q1 2026.
• A 5-year average of $210.4 million and a median of $209.4 million in 2024 frame the typical range for Common Equity.
• Across the five-year window, Common Equity climbed 3.3% in 2022 and sank 33.5% in 2024, its largest moves.
• Over 5 years, Common Equity stood at $285.6 million in 2022, then fell by 25.67% to $212.3 million in 2023, then slipped by 27.45% to $154.0 million in 2024, then slipped by 6.83% to $143.5 million in 2025, then decreased by 4.31% to $137.3 million in 2026.
• The last three Common Equity figures came in at $137.3 million (Q2 2026), $133.9 million (Q1 2026), and $143.5 million (Q4 2025), per Business Quant data.